---
title: "Citas"
author: "Luis Andrés Rojas García Exp. 279465"
date: "`r format(Sys.time(), '%B %d , %Y')`"
output: 
    html_document:
        toc: true
        toc_depth: 6
        collapsed: false
        smooth_scroll: true
bibliography: referencias.bib
csl: apa.csl
---

# Referencias para la tesis

# 2. Antecedentes

## 2.1. Características de los coronavirus y de SARS-CoV-2

### 2.1.1. Origen de la COVID-19

1. [@zhou2020pneumonia]

2. [@sharma2021covid]

3. [@sharma2021covid]

4. [@li2020evolutionary; @sharma2021covid]

### 2.1.2. Familia *coronaviridae*

5. [@GAURAV2019271; @BURRELL2017437]

6. [@BURRELL2017437; @murugan2021covid]

7. [@BURRELL2017437]

8. [@BURRELL2017437]

9. [@BURRELL2017437]

10. [@BURRELL2017437; @andersen2020proximal; @murugan2021covid]

### 2.1.3. Estructura los Coronavirus

11. [@GAURAV2019271; @BURRELL2017437]

### 2.1.4. Genoma de SARS-CoV-2

12. [@GAURAV2019271; @murugan2021covid]

13. [@GAURAV2019271; @murugan2021covid; @BURRELL2017437]

14. [@BURRELL2017437]

15. [@BURRELL2017437]

16. [@GAURAV2019271; @BURRELL2017437]

17. [@BURRELL2017437]

18. [@BURRELL2017437; @murugan2021covid]

19. [@dhama2022global; @tao2021biological]

### 2.1.5 Ciclo de replicación de SARS-CoV-2

20. [@salian2021covid; @pizzato2022sars; @harrison2020mechanisms]

21. [@salian2021covid]

22. [@salian2021covid; @harrison2020mechanisms; @pizzato2022sars; @BURRELL2017437]

23. [@salian2021covid; @pizzato2022sars]

24. [@BURRELL2017437]

25. [@harrison2020mechanisms; @pizzato2022sars; @BURRELL2017437]

26. [@harrison2020mechanisms]

27. [@harrison2020mechanisms; @pizzato2022sars]

28. [@BURRELL2017437; @harrison2020mechanisms]

29. [@BURRELL2017437]

30. [@harrison2020mechanisms; @pizzato2022sars]

### 2.1.6. Aparición del SARS-CoV-2

31. [@salian2021covid]

32. [@li2020evolutionary]

33. [@salian2021covid]

34. [@li2020evolutionary]

35. [@salian2021covid]

36. [@salian2021covid]

37. [@xiao2020isolation] en [@sharma2021covid]

38. [@xiao2020isolation] en [@sharma2021covid]

## 2.2. Pandemia por COVID-19

### 2.2.1 Transmisión del SARS-CoV-2

39. [@harrison2020mechanisms]

40. [@harrison2020mechanisms; @salian2021covid; @lotfi2020covid; @sharma2021covid]

41. [@morawska2020airborne]

42. [@morawska2020airborne]

43. [@salian2021covid; @sharma2021covid]

44. [@sharma2021covid; @lotfi2020covid; @harrison2020mechanisms]

45. [@sharma2021covid]

46. [@sharma2021covid]

47. [@sharma2021covid; @harrison2020mechanisms]

### 2.2.2. Manifestaciones clínicas

48. [@salian2021covid]

49. [@lotfi2020covid]

50. [@salian2021covid; @lotfi2020covid]

51. [@salian2021covid]

52. [@lotfi2020covid]

53. [@harrison2020mechanisms]

54. [@ssaludcovid]

#### 2.2.2.1. Respuestas inmunitarias ante el SARS-CoV-2

55. [@murugan2021covid]

56. [@murugan2021covid; @BURRELL2017437; @harrison2020mechanisms]

#### 2.2.2.2. Patogenesis del SARS-CoV-2

57. [@pizzato2022sars]

58. [@harrison2020mechanisms]

59. [@liao2020single; @harrison2020mechanisms]

60. [@harrison2020mechanisms]

61. [@puntmann2020outcomes; @liao2020single; @qin2020dysregulation; @chen2021sars; @nicholls2003lung; @channappanavar2017pathogenic; @varga2020endothelial; @hadjadj2020impaired; @harrison2020mechanisms]

#### 2.2.2.2. Etapas de la enfermedad

62. [@lauer2020incubation]

##### 2.2.2.2.1. Periodo de incubación

63. [@cdc2022CasesData]

64. [@murugan2021covid; @lauer2020incubation; @salian2021covid; @pizzato2022sars; @harrison2020mechanisms]

65. [@backer2020incubation; @lauer2020incubation]

66. [@linton2020incubation; @lauer2020incubation]

67. [@virlogeux2016comparison; @varia2003investigation; @lauer2020incubation]

68. [@acosta2022covid]

##### 2.2.2.2.2. Pacientes con sintomatología leve

69. [@lauer2020incubation]

70. [@oran2020prevalence]

71. [@he2021proportion]

##### 2.2.2.2.3. Infección clínica

72. [@salian2021covid]

73. [@cdc2022CasesData]

74. [@secsalud2021covid]

75. [@tsai2021clinical]


##### 2.2.2.2.4. Casos hospitalizados

76. [@cdc2022CasesData]

77. [@murugan2021covid]

78. [@fan2020clinical]

##### 2.2.2.2.5. Asistencia respiratoria

79. [@salian2021covid]

80. [@gibson2020covid; @acosta2022covid]

##### 2.2.2.2.6. Fallecimiento de los pacientes

81. [@cdc2022CasesData; @secsalud2021covid]

82. [@KLOK2020145; @murugan2021covid]

83. [@gibson2020covid]

84. [@wu2020risk; @gibson2020covid]

85. [@zhang2023risk]

86. [@wu2020estimating; @zhang2023risk]

### 2.2.3. Técnicas de diagnóstico y detección

87. [@kevadiya2021diagnostics]

88. [@murugan2021covid; @sharma2021covid]

89. [@guan2020clinical; @murugan2021covid]

90. [@guan2020clinical]

91. [@vandenberg2021considerations]

92. [@long2020diagnosis]

#### 2.2.3.1. Principales técnicas de detección de SARS-CoV-2

##### 2.2.3.1.1. RT-PCR

93. [@kevadiya2021diagnostics]

94. [@vandenberg2021considerations]

95. [@sharma2021covid]

96. [@chan2020familial]

97. [@corman2020detection]

98. [@sharma2021covid]

99. [@murugan2021covid]

100. [@vogels2020salivadirect]

101. [@murugan2021covid; @kevadiya2021diagnostics; @vandenberg2021considerations; @long2020diagnosis]

102. [@kevadiya2021diagnostics; @vandenberg2021considerations]

103. [@murugan2021covid]

##### 2.2.3.1.2. Radiología

104. [@murugan2021covid; @sharma2021covid]

105. [@murugan2021covid]

106. [@murugan2021covid; @sharma2021covid; @kevadiya2021diagnostics; @long2020diagnosis]

107. [@parekh2020review]

108. [@murugan2021covid; @kevadiya2021diagnostics]

109. [@wang2020temporal]

110. [@bernheim2020chest]

111. [@long2020diagnosis]

112. [@fang2020sensitivity]

113. [@sharma2021covid]

114. [@murugan2021covid]

115. [@loey2020within; @ozturk2020automated; @rahimzadeh2020modified; @huang2021artificial]

##### 2.2.3.1.3. Ensayos inmunológicos

116. [@murugan2021covid]

117. [@sharma2021covid]

118. [@kevadiya2021diagnostics]

119. [@safiabadi2021tools]

120. [@ejazi2021antibody]

121. [@murugan2021covid; @kevadiya2021diagnostics]

122. [@lv2020cross; @long2020antibody; @murugan2021covid]

123. [@kevadiya2021diagnostics]

124. [@kevadiya2021diagnostics]

125. [@safiabadi2021tools]

126. [@safiabadi2021tools]

127. [@safiabadi2021tools]

128. [@lab2022chopoa]

129. [@lab2022chopob]

130. [@amunet2022elisa]

##### 2.2.3.1.4. Kits de pruebas rápidas

131. [@sharma2021covid]

132. [@kevadiya2021diagnostics]

133. [@cdc2023rat]

134. [@yamayoshi2020comparison]

135. [@sharma2021covid; @cdc2023rat]

#### 2.2.3.2 Consideraciones de la OMS

136. [@10665-330861]

137. [@murugan2021covid; @kevadiya2021diagnostics; @liu2020positive]

138. [@surveillance2020owho]

139. [@10665-330861]

140. [@10665-330861]

141. [@10665-330861]

142. [@10665-330861]

143. [@10665-330861]

144. [@10665-330861]

145. [@10665-330861]

146. [@WHOpolicybrief2022]

#### 2.2.3.3 Técnicas aprobadas e implementadas en México

147. [@palomino2022identificacion]

148. [@cofepris2022pruebas]

149. [@cofepris2020pruebas]

150. [@indrelaboratorios]

### 2.2.4. Principales tratamientos y terapias implementados

148. [@murugan2021covid]

149. [@heymann2020covid; @sharma2021covid]

150. [@salian2021covid]

151. [@lotfi2020covid]

152. [@sharma2021covid]

### 2.2.5. Epidemiología de COVID-19

#### 2.2.5.1. Medidas de prevención epidemiológica para la detención de la pandemia

153. [@cdc2023proteccion]

154. [@secsaludprevencion]

155. [@whocoronavirus]

156. [@krittanawong2022covid]

##### 2.2.5.1.1. Vacunación

157. [@da2022two]

158. [@who2023vaccines]

#### 2.2.5.2. Factores de riesgo y protección

159. [@zhang2023risk]

160. [@pijls2021demographic; @zhang2023risk]

161. [@ayoub2020characterizing; @zhang2023risk]

162. [@wu2020estimating; @zhang2023risk]

163. [@liu2020positive; @zhang2023risk]

164. [@li2021epidemiology; @zhang2023risk]

165. [@guan2020comorbidity; @zhang2023risk]

166. [@bae2021impact; @zhang2023risk]

167. [@gao2021risk; @zhang2023risk]

168. [@hosseini2019type; @zhang2023risk]

169. [@hodgson2021defines; @zhang2023risk]

170. [@zhang2021safety; @wu2021safety; @zhang2023risk]

171. [@pawlowski2021fda; @zhang2023risk; @thompson2021interim]

#### 2.2.5.3. Epidemiología en México durante el incio de la pandemia

172. [@suarez2020epidemiologia]

### 2.2.6. Efectos de la pandemia en la población

#### 2.2.6.1. Diferencias en la edad

173. [@zhang2023risk]

174. [@kauhanen2023systematic]

https://www.cureus.com/articles/115491-effects-of-covid-19-on-older-adults-physical-mental-emotional-social-and-financial-problems-seen-and-unseen#!/
https://www.paho.org/en/disasters-newsletter-no131-impact-covid-19-pandemic-mental-health-population
https://idp.springer.com/authorize?response_type=cookie&client_id=springerlink&redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12062-021-09330-w
https://www.bma.org.uk/advice-and-support/covid-19/what-the-bma-is-doing/the-impact-of-the-pandemic-on-population-health-and-health-inequalities
https://www.kff.org/mental-health/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use/
https://idp.springer.com/authorize?response_type=cookie&client_id=springerlink&redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00787-022-02060-0#citeas
https://journals.sagepub.com/doi/full/10.1177/00420980211041018
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00034-2/fulltext
https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1665-05652020000200265
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613797/

175. [@inegi2022estadisticas]

<br>

## 3. Fuentes de consulta

<br>







